51558-25-9

Basic information

• Product Name: 2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine
• Synonyms: 2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine;2-(4-Methoxyphenyl)-2-MethylpropylaMine
• CAS NO: 51558-25-9
• Molecular Formula: C₁₁H₁₇NO
• Molecular Weight: 179.25878
• Mol File: 51558-25-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine(51558-25-9)
• EPA Substance Registry System: 2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine(51558-25-9)

Safety Data

• Hazardous Substances Data: 51558-25-9(Hazardous Substances Data)

Usage

Description

2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine, also known as metaraminol, is a synthetic adrenergic drug that functions as a potent sympathomimetic amine. It is recognized for its ability to stimulate alpha-adrenergic receptors, leading to vasoconstriction and an increase in blood pressure.
Used in Pharmaceutical Industry:
2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine is used as a vasopressor agent for the treatment of hypotension. It is particularly effective in managing low blood pressure during critical situations such as shock or during surgical procedures.
Used in Emergency Medicine:
2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine is used as an emergency medication to rapidly increase blood pressure in patients experiencing severe hypotension. Its quick onset of action makes it a crucial component in emergency and critical care settings.
Used in Anesthesiology:
2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine is used as a countermeasure for low blood pressure associated with septic shock and spinal anesthesia, helping to stabilize patients and improve perfusion.
Despite potential side effects, 2-(4-Methoxyphenyl)-2-Methylpropan-1-aMine has demonstrated significant efficacy in raising blood pressure and enhancing patient outcomes in cases of severe hypotension. It is administered intravenously to ensure rapid delivery and effect.

Upstream product

• 5351-07-5 2-(4-methoxy-phenyl)-2-methyl-propionitrile 
• 55770-61-1 2-(4-Hydroxyphenyl)-2-methylpropionitrile 
• 51558-05-5 rac-2-(4-ethoxy-phenyl)-propionitrile 

Downstream Products

• 210551-85-2 4-(2-amino-1,1-dimethyl-ethyl)-phenol 
• 1164109-82-3 1-((2-methyl-2-[4-(methyloxy)phenyl]propyl)amino)-3-(phenyloxy)-2-propanol 
• 596115-16-1 N-[2-(4-methoxyphenyl)-2-methylpropyl]-N-[4-(trifluoromethoxy)benzyl]amine 
• 51558-26-0 2-methyl-2-(4-methoxyphenyl)-1-propanamine hydrochloride 
• 1227056-70-3 5-ethyl-N-[2-methyl-2-[4-(methyloxy)phenyl]propyl]-2-pyrimidinamine 

Relevant articles and documents

N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

Effects of various bases on acid-catalyzed amination of 2-chloro-5-ethylpyrimidine: Synthesis of PPARpan agonist GW693085

Figure presented A unique buffering effect of various bases, i-Pr 2NEt and CaCO3 in particular, was observed for the acid-catalyzed chloro displacement of 2-chloro-5-ethylpyrimidine with a 2-methyl-2-phenylpropanamine. The use of the

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.